healthletics oral bpc-157 Is Banned? vs. Injectable Forms Explained BPC 157: Speed Up Healing

STEP UP directly compared 7.2 mg with 2.4 mg and placebo over 72 weeks: FDA prescribing information

This is the protocol that typically yields the best balance of results and side effects

Results demonstrated that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo. Critically, the peptide produced no clinically significant alterations in IGF-1 levels, no glucose intolerance or insulin resistance, and no anti-AOD9604 antibodies in any participant

Experimental Dermatology, 28 (3), 219-224

It is also a strong antioxidant

An incomplete name can conceal differences in calculated mass, counterion content and total material composition